Guadagnuolo V, Papayannidis C, Iacobucci I, et al. SIRPB1: biomarker of response to 5-azacitidine treatment in MDS and AML patients. EHA 2017, abstract E1201.
Fysieke inactiviteit de grootste modificeerbare risicofactor in de geneeskunde
jan 2024 | Leukemie, Lymfoom, MDS, MM, MPN